Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Investing.com -- Shares of Genmab A/S (CSE: GMAB) rose after the Danish biotech company reported second-quarter earnings that beat expectations, driven by strong sales of Darzalex and positive trial ...

Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently ...

Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

Genmab A/S (NASDAQ:GMAB) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 16, Genmab A/S (NASDAQ:GMAB ...

DARZALEX ® combination therapy significantly reduced the risk of disease progression or death compared to a preferred regimen alone. 1,2 "This daratumumab combination regimen for newly diagnosed ...

WEDNESDAY, Aug. 7, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and ...

Two Democratic senators on Monday tore into their Republican counterparts for "sneaking" a provision into their party's ...

Genmab (CSE: GMAB) A/S (NASDAQ: GMAB), a pharmaceutical company specializing in antibody therapeutics for cancer and maintaining an impressive 96.1% gross profit margin, has reported its net sales for ...